EYEPOINT, INC reports a Return on Equity (ROE) of -117.84%.

What is EYPT's dividend yield?

EYEPOINT, INC offers a dividend yield of 0.00%.

What is EYPT's Quality Score?

Our AI rates EYPT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy EYPT?

Our AI Timing Score for EYPT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does EYPT belong to?

EYEPOINT, INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

EYPT (NASDAQ) Stock Analysis | EYEPOINT, INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

EYPT AI Analysis Summary

Our AI summary for EYPT: EYEPOINT, INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -117.84%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

EYPT

EYEPOINT, INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 12.25

-0.61 (-4.74%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-117.8%

ROE

-94.2%

ROA

0.00%

Div Yield

EYEPOINT, INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 12.25 Price -0.61 (-4.74%) Day Change	NEWS SCORE: 89

EYPT, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	12.25
PBV / Sector	4.68 / 5.20
Earning Per Share	-3.09

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	19.82 M GREAT
Average 1W Daily Value	20.35 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3,566.63 / 98.71
NPM Average (%) / Sector	-1,001.86 / -1,721.76
NPM Change Average (%) / Sector	146.43 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-94.23 / 27.02
ROA Average (%) / Sector	-53.17 / -368.17
ROA Change Average (%) / Sector	35.93 / 5,404.12 GREAT
ROE (%) / Sector	-117.84 / 3.47
ROE Average (%) / Sector	-73.04 / 6.51
ROE Change Average (%) / Sector	30.43 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:48
Symbol	EYPT
Name	EYEPOINT, INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	83.84 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,078.20 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 480 Pleasant Street, Watertown, MA, United States, 02472

Phone: 617 926 5000

Website: https://eyepoint.bio

Employees: 214

Sector: Healthcare >> Biotechnology

Description: EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.